So what makes PureGym so special? They keep prices low and make sure the pricing is simple and easy to understand. Their gyms are packed with state-of-the-art equipment and are maintained to the highest standard. With up to 50 free classes every week, you can pop in at your leisure. Their gyms are open all day, every day and the best thing is there is no contract so you are free to join and leave if your circumstances change.
CoolSculpting works by taking advantage of the fact that fat cells are more sensitive to cold than the other cells around them. This basic scientific fact was first discovered in 1970 by doctors observing children who sucked on popsicles for hours, and ended up having first soreness, and later dimples, caused by loss of fat cells! Fast forward about 20 years, and Harvard scientists revisited this fact, and realized that they could turn this science into a system for aesthetic sculpting of fatty bulges. The key was to find the ‘sweet spot’ of time and temperature, which would kill some fat cells but not damage surrounding structures such as skin. They called the public company that makes the systems Zeltiq. The proof of the success of this concept and treatment: Zeltiq was bought out by Allergan in 2016 for whopping 2.5 billion! This was the largest sale of a single medical device company in history.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Dr. David P. Rapaport, founder and Medical Director of Coolspa, created Coolspa to address the need in New York for a patient-centric, high quality facility where clients could experience top-tier body contouring in a relaxed, comfortable setting. Most importantly, the Coolspa ethos is based on patient education. Only by being educated about their condition, all relevant treatment options, advantages and disadvantages of those options, can patients make optimal treatment decisions.
1 July 2015: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.